UTHR Shorts Retreat as Stock Surges 6.7% Past Its Peer Group

United Therapeutics stands apart from its closest peers this week: while the median correlated name fell 1.8%, UTHR climbed 6.7% to $591.20, driven by a short position that collapsed rather than held.

The short squeeze story is the sharpest angle. Short interest dropped 31.6% over the week to 5.8% of the free float, roughly 2.5 million shares, a move that is 3.2 standard deviations below the stock's typical weekly change over the past year. That is not gradual covering; it is a significant unwind in a short position that had been sitting at 3.6 to 3.7 million shares for most of the preceding two weeks. The borrow market is relaxed throughout this: cost to borrow is just 0.43%, and availability is 2,617%, meaning shares available to lend vastly outnumber those already borrowed. There is no squeeze pressure in the lending pool. The covering appears to be a positioning decision, not a forced exit. Options positioning shifted in the same direction. The put/call ratio has fallen to 0.59, well below its 20-day mean of 0.74, and the z-score of minus 1.1 confirms call buyers are still more active than usual, though the extreme bullishness of last week, when the PCR hit 0.52, has eased slightly. The ORTEX short score also dropped sharply, from just below 50 on October 22 down to 42.2 by October 27, a move that reflects the rapid short covering more than any fundamental shift.

The Street is broadly constructive, though not unanimously. The consensus mean target is $672, about 14% above the current price. RBC Capital trimmed its target fractionally to $697 on October 22 while keeping its Outperform rating, and Leerink Partners raised to $725 just days before earnings. The outlier remains Goldman Sachs, which initiated in late September with a Sell and a $321 target, a level less than half the current price and far below every other published estimate on the register. Morgan Stanley sits at Equal-Weight with a $566 target, below the current stock price. That split is genuine: most analysts see meaningful upside, while Goldman's bear case centres on Tyvaso franchise concentration and competitive risk from Liquidia's Yutrepia taking more pulmonary arterial hypertension share than the bulls expect. Valuation offers some support: the trailing PE is 17.9x, and EV/EBITDA is 12.1x, both having drifted lower over the past 30 days even as the stock rose, compressing multiples in the right direction for value-oriented holders. EPS momentum over the past 30 days ranks in the 93rd percentile of the ORTEX universe, one of the strongest readings in the dataset.

CEO Martine Rothblatt sold approximately $5.5 million of stock on October 26 across multiple tranches at prices ranging from $585 to $593. All transactions were executed under a pre-arranged 10b5-1 plan, which limits their signal value. Rothblatt's net 90-day disposals total around $20.7 million, consistent with a long-running plan-based selling programme rather than any fresh conviction on direction. Her listed shareholding of 668,728 shares remains intact. On the institutional side, BlackRock added 99,096 shares in the latest reported quarter to reach 12.3% of shares outstanding, while State Street added 108,519 shares. Wellington Management trimmed its stake below the 5% disclosure threshold, down to 3.2% from 5.7%.

Medicaid data from the Centers for Medicare and Medicaid Services adds a note of caution in the background. Medicaid prescriptions for United Therapeutics products have fallen for three consecutive quarters, reaching 5,208 prescriptions as of Q1 2026. Medicaid reimbursed dollars were down 11% against the same quarter a year earlier. None of the alt-data datasets have been measured to lead the company's reported financials, so these figures are colour on channel trends rather than a leading indicator of the next print. The next earnings report is scheduled for November 4.

What to watch is whether short interest rebuilds from here or the covering proves durable, with the ORTEX short score's move from 50 to 42 over three days now the clearest measure of how much the positioning picture has already changed.